Journals / Abant Tıp Dergisi / 2012 / Cilt: 1 - Sayı: 2

Approach of dyslipidemia; as a cardiovascular risk factor

Kardiyovasküler risk faktörü olarak dislipidemilere yaklaşım

Pages
89–93
Publication Date
2012-05-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Individuals must be separated according to risk scores for cardiovascular disease and dyslipidemia approach should be planned accordingly this risk scoring.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cardiovascular diseases are the leading cause of mortality continues to be all over the world.
📊
Key Findings & Data:Both primary prevention and secondary prevention with lipid-lowering therapy along with lifestyle changes and drug therapy has been shown to decrease the development of cardiovascular events.
💡
Conclusion & Impact:Individuals must be separated according to risk scores for cardiovascular disease and dyslipidemia approach should be planned accordingly this risk scoring.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dislipidemi · kalp ve damar hastalığı · risk faktörleri

Abstract

Cardiovascular diseases are the leading cause of mortality continues to be all over the world. Dyslipidemia is an important cardiovascular risk factor and preventable with lifestyle changes and drug therapy. Both primary prevention and secondary prevention with lipid-lowering therapy along with lifestyle changes and drug therapy has been shown to decrease the development of cardiovascular events. The risk scoring of patients is one of the important points in the treatment of dyslipidemia. Individuals must be separated according to risk scores for cardiovascular disease and dyslipidemia approach should be planned accordingly this risk scoring.

Özet

Kalp ve damar hastalıkları tüm dünyada önde gelen mortalite nedeni olmaya devam etmektedir. Dislipidemi ise kalp ve damar hastalıklarında gerek yaşam tarzı değişiklikleri gerek ise ilaç tedavisi ile düzeltilebilen önemli bir risk faktörüdür. Gerek primer koruma amaçlı gerekse sekonder koruma amaçlı lipid düşürücü tedavi ile yaşam tarzı değişiklikleri ve ilaç tedavisi birlikte kardiyovasküler olay gelişiminde azalma olduğu gösterilmiştir. Dislipidemi tedavisinde önemli noktalardan birisi de hastaların risk skorlamasıdır. Bireyler kalp damar hastalıkları açısından risk gruplarına ayrılmalı ve dislipidemi yaklaşımı buna göre planlanmalıdır.

🔖

Cite This Article

ÖZTÜRK, S., ÖZTÜRK, S. (2012). Approach of dyslipidemia; as a cardiovascular risk factor. Abant Tıp Dergisi, Cilt: 1 - Sayı: 2, 89–93. https://ajindex.com/articles/449279

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. World Health Organization. Cardiovascular diseases (CVDs) [ online ]. Available from URL: http:// www.who.int/mediacentre/ factsheets/fs317/en/inex.html 2. Murray CJL, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study Lancet 1997; 349: 1498-1504.
  2. Emberson JR, Whincup PH, Morris RW Walker M. Re- assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal 2003; 24: 1719–26. World Health Organization. Reducing risks, promoting healthy life. The world health report 2002. World Health Organization: Gaining Health: The European Strategy for the Prevention and Control of non- communicable diseases. WHO Regional Committee for Europe www.euro.whu.int/Document/RC56/edoc08. De Backer G; EUROASPIRE II Study Group. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROAS- PIRE II. Atheroscler Suppl. 2002; 13-6;16-7.
  3. De Sutter J, De Bacquer D, Kotseva K, Sans S, Pyorala K, Wood D, De Backer G; EUROASPIRE II Study Group. Scree- ning of family members of patients with premature coro- nary heart disease; results from the EUROASPIRE II family survey. Eur Heart J. 2003; 24: 249-57.
  4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravas- tatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504.
  5. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of choleste- rol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005; 21: 1389-99.
  6. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Nati- onal Heart, Lung, and Blood Institute;American College of Cardiology tion.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-39.
  7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V,